Georgios Kyriakos1, Lourdes Victoria Quiles-SÁnchez2, Evangelos Diamantis3, Paraskevi Farmaki4, Nikolaos Garmpis5,6, Christos Damaskos7,8, Spyridon Savvanis9, Alexandros Patsouras10, Athanasia Stelianidi4, Errika Voutyritsa6, Vasiliki E Georgakopoulou11,12, Anna Garmpi13. 1. Seccion de Endocrinologia y Nutrition, Hospital General Universitario Santa Lucia, Cartagena, Spain. 2. Centro de Salud Jesús Marín, Murcia, Spain. 3. Department of Endocrinology and Diabetes Center, G. Gennimatas General Hospital, Athens, Greece. 4. First Department of Pediatrics, Agia Sofia Children's Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece. 5. Second Department of Propedeutic Surgery, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece. 6. N.S. Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, Athens, Greece. 7. N.S. Christeas Laboratory of Experimental Surgery and Surgical Research, Medical School, National and Kapodistrian University of Athens, Athens, Greece x_damaskos@yahoo.gr. 8. Renal Transplantation Unit, Laiko General Hospital, Athens, Greece. 9. Internal Medicine Department, Elpis General Hospital, Athens, Greece. 10. Second Department of Internal Medicine, Tzanio General Hospital, Piraeus, Greece. 11. Department of Pulmonology, Laiko General Hospital, Athens, Greece. 12. First Department of Pulmonology, Sismanogleio Hospital, Athens, Greece. 13. First Department of Propedeutic Internal Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Abstract
BACKGROUND/AIM: Lipid-lowering drugs have been suggested to affect neurocognitive function. This review aimed to give the latest evidence on the way these agents affect neurocognitive function based on clinical trials. MATERIALS AND METHODS: A systematic search concerning original studies from 2015 to 2020 was performed through the databases PubMed, EMBASE and Cochrane, according to the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines. The trials enrolled numerous patients and were conducted in different areas of the world. The terms used are cholesterol, lipid-lowering drugs, statins and cognitive function. RESULTS: Eleven randomized trials met the inclusion criteria. The trials included patients suffering from cardiovascular conditions. In particular, patients with coronary heart disease, coronary heart disease risk equivalents and hypercholesterolemia were tested. The trials included evolocumab, alirocumab, statin, ezetimibe or placebo. CONCLUSION: Lipid-lowering drugs seem to have no significant effect on neurocognitive function, but further research specifically focused on this matter is needed. Copyright
BACKGROUND/AIM: Lipid-lowering drugs have been suggested to affect neurocognitive function. This review aimed to give the latest evidence on the way these agents affect neurocognitive function based on clinical trials. MATERIALS AND METHODS: A systematic search concerning original studies from 2015 to 2020 was performed through the databases PubMed, EMBASE and Cochrane, according to the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines. The trials enrolled numerous patients and were conducted in different areas of the world. The terms used are cholesterol, lipid-lowering drugs, statins and cognitive function. RESULTS: Eleven randomized trials met the inclusion criteria. The trials included patients suffering from cardiovascular conditions. In particular, patients with coronary heart disease, coronary heart disease risk equivalents and hypercholesterolemia were tested. The trials included evolocumab, alirocumab, statin, ezetimibe or placebo. CONCLUSION:Lipid-lowering drugs seem to have no significant effect on neurocognitive function, but further research specifically focused on this matter is needed. Copyright
Authors: Jennifer G Robinson; Robert S Rosenson; Michel Farnier; Umesh Chaudhari; William J Sasiela; Laurence Merlet; Kathryn Miller; John J P Kastelein Journal: J Am Coll Cardiol Date: 2017-02-07 Impact factor: 24.094
Authors: Dean J Kereiakes; Jennifer G Robinson; Christopher P Cannon; Christelle Lorenzato; Robert Pordy; Umesh Chaudhari; Helen M Colhoun Journal: Am Heart J Date: 2015-03-13 Impact factor: 4.749
Authors: Warren B Zigman; Nicole Schupf; Edmund C Jenkins; Tiina K Urv; Benjamin Tycko; Wayne Silverman Journal: Neurosci Lett Date: 2007-02-11 Impact factor: 3.046
Authors: Jennifer G Robinson; Michel Farnier; Michel Krempf; Jean Bergeron; Gérald Luc; Maurizio Averna; Erik S Stroes; Gisle Langslet; Frederick J Raal; Mahfouz El Shahawy; Michael J Koren; Norman E Lepor; Christelle Lorenzato; Robert Pordy; Umesh Chaudhari; John J P Kastelein Journal: N Engl J Med Date: 2015-03-15 Impact factor: 91.245
Authors: Christopher P Cannon; Bertrand Cariou; Dirk Blom; James M McKenney; Christelle Lorenzato; Robert Pordy; Umesh Chaudhari; Helen M Colhoun Journal: Eur Heart J Date: 2015-02-16 Impact factor: 29.983
Authors: John J P Kastelein; Henry N Ginsberg; Gisle Langslet; G Kees Hovingh; Richard Ceska; Robert Dufour; Dirk Blom; Fernando Civeira; Michel Krempf; Christelle Lorenzato; Jian Zhao; Robert Pordy; Marie T Baccara-Dinet; Daniel A Gipe; Mary Jane Geiger; Michel Farnier Journal: Eur Heart J Date: 2015-09-01 Impact factor: 29.983